The National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) both recommended the use of Oncotype Dx RS testing in patients with ER + /HER2 − breast cancers [15, 16]. The gene discussed is ESR1; the disease is breast carcinoma.